

## **NEWS RELEASE**

### **FOR IMMEDIATE RELEASE**

## **Sequella Receives U.S. Patent for Novel Therapeutic Compounds**

ROCKVILLE, Md, October 4, 2005-- Sequella, Inc., a privately held biotechnology company developing products for infectious diseases, today announced the issuance of its Patent No. 6,951,961 entitled "Methods of Use and Compositions for the Diagnosis and Treatment of Infectious Disease" by the U.S. Patent and Trademark Office for Sequella's proprietary diamine compounds.

"This fundamental patent provides broad coverage for compositions of matter and uses of Sequella's proprietary diamine anti-infectives for treatment of diseases caused by microorganisms, particularly tuberculosis," said Dr. Carol Nancy, CEO of Sequella. "The patent demonstrates our commitment to commercializing best-in-class, new medicines to treat infectious disease," she said.

The patent is part of a foundational intellectual property estate for Sequella's proprietary diamine compounds, with broad issued use claims for anti-viral and anti-infective applications. The patent is a key component of Sequella's business strategy to commercialize new products through internal R&D activities and alliances with corporate partners.

The Sequella drug discovery program researches novel small molecule and natural product-based therapeutics for infectious diseases. Sequella's first drug candidate, SQ109, has completed IND-directed toxicology studies and an IND is expected to be filed with the FDA before the end of the year. Developed in partnership with the NIH, SQ109 is a new diamine anti-mycobacterial drug with a novel mechanism of action. SQ109 is bactericidal, orally bioavailable, concentrates in lung and spleen, has a long half-life, and is effective against drug-resistant TB. In addition, SQ109 may be useful as an anti-fungal therapeutic for *Candida* sp.

### **About Sequella, Inc.**

Sequella, Inc. is a clinical stage biotechnology company, developing and commercializing novel infectious disease diagnostic and therapeutic products. The company's lead product candidate, the Transdermal Patch for diagnosis of active TB disease, is being tested in an international phase III clinical trial, with over 50% of patients already enrolled in six clinical centers. Sequella conducts discovery and pre-clinical research at its Rockville headquarters, which houses chemistry and microbiology laboratories, and a BSL-3 facility. For more information, please visit [www.sequella.com](http://www.sequella.com).

### **Forward-Looking Statement**

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts and generally can be identified by the use of phrases such as "believe," "expect," "plan," "estimate," "potential," "opportunity," "project," and similar terms. Actual results could differ significantly from results discussed, including whether products can be successfully developed and commercialized; whether Sequella will enter into future alliances with corporate partners; and other uncertainties. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law.

### **MEDIA CONTACT:**

Henrik Wranaker  
301-762-7776  
[HenrikWranaker@sequella.com](mailto:HenrikWranaker@sequella.com)